A recent report from Holland & Knight provides an overview of important health policy and drug-related developments taking place in the United States as of June 16, 2026. This update covers new FDA actions, changes in drug pricing policies, and other federal health initiatives that may affect patients and healthcare providers.

Key takeaways

  • The FDA has announced several new drug approvals and safety updates for June 2026.
  • Drug pricing negotiations under the Inflation Reduction Act continue to progress, with new details on selected medications.
  • Federal agencies are launching new public health campaigns targeting chronic disease prevention.
  • Medicare and Medicaid policies are being updated to expand telehealth access and mental health services.
  • Congress is considering new legislation to address pharmacy benefit manager practices and drug affordability.

FDA approvals and safety updates

The Food and Drug Administration approved several new drugs in June 2026, including treatments for rare diseases and common chronic conditions. According to the Holland & Knight report, these approvals reflect the agency’s ongoing commitment to bringing innovative therapies to market while maintaining safety standards. The FDA also issued new safety warnings for certain existing medications, urging healthcare providers to monitor patients for potential side effects.

The agency continues to review applications for biosimilar products, which could increase competition and lower costs for patients. Regulatory experts say these approvals are part of a broader trend toward more rapid review times for drugs that address unmet medical needs.

Drug pricing and the Inflation Reduction Act

The Inflation Reduction Act’s drug pricing provisions remain a central focus of federal health policy in 2026. The report notes that the Centers for Medicare and Medicaid Services has released updated guidance on the negotiation process for high-cost drugs. The first set of negotiated prices is expected to go into effect soon, potentially lowering out-of-pocket costs for Medicare beneficiaries.

Pharmaceutical companies continue to challenge certain aspects of the law in court, arguing that the negotiation process is unconstitutional. Legal experts cited in the report say that court rulings later this year could have major implications for the future of drug pricing reform.

Telehealth and mental health expansion

Federal policymakers are working to make pandemic-era telehealth flexibilities permanent, according to the report. Medicare has extended coverage for virtual visits, and new bills in Congress aim to remove geographic restrictions that limit telehealth use. The report highlights that mental health services are a key area of expansion, with increased funding for crisis hotlines and community mental health centers.

Providers say that continued telehealth access is critical for reaching rural populations and patients with limited mobility. However, concerns about fraud and quality of care remain topics of ongoing debate among lawmakers.

Pharmacy benefit manager regulations

The Biden administration and some members of Congress are pushing for stricter oversight of pharmacy benefit managers (PBMs). The report states that proposed legislation would require PBMs to be more transparent about their pricing practices and rebates. Supporters say this could lower prescription drug costs for consumers, while opponents warn it may disrupt existing contracts and supply chains.

The Federal Trade Commission has also launched investigations into several large PBM companies, examining whether their business practices unfairly raise drug prices or limit patient access to pharmacies.

Public health initiatives

Federal health agencies are rolling out new public health campaigns focused on preventing chronic diseases such as diabetes, heart disease, and obesity. The report highlights efforts to improve nutrition labeling, promote physical activity, and increase access to preventive screenings. These initiatives come as data show rising rates of chronic conditions across all age groups in the United States.

Additionally, the Department of Health and Human Services is investing in data infrastructure to better track disease outbreaks and health disparities. Officials say this will help target resources to communities that need them most.

Frequently Asked Questions

What did the FDA approve in June 2026?

The FDA approved several new drugs in June 2026, including treatments for rare diseases and chronic conditions, according to the Holland & Knight report. The agency also updated safety warnings for existing medications and is reviewing more biosimilar applications to increase treatment options and competition.

How will the Inflation Reduction Act affect drug prices in 2026?

The first round of Medicare drug price negotiations under the Inflation Reduction Act is moving forward, with new pricing expected to take effect soon. This could lower costs for seniors, though legal challenges from pharmaceutical companies may delay or alter the program, as noted in the report.

Are telehealth services being made permanent?

Yes, federal policymakers are working to make many pandemic-era telehealth flexibilities permanent, especially for mental health services. Medicare has extended coverage, and new legislation seeks to remove remaining geographic restrictions, according to the Holland & Knight update.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.